CJC-1295 (DAC) belongs to tetra-substituted peptide hormones classification. CJC-1295 (DAC) contains 30 amino acids. The modified version of GRF 1-29 demonstrates a high affinity towards GHRH receptors. The molecular weight of CJC-1295 (DAC) is 3647.28 and molecular formula is C165H269N47O46. The compound was originally developed by a team of Canadian researchers to increase half-life of growth hormone releasing hormone. Research studies confirmed that the synthetic complex increases GHRH and IGF-1 secretion but not prolactin. CJC-1295 promotes lipolysis and protein biosynthesis. The biomolecule arrangement of CJC-1295 (DAC) prevents rapid degradation and improves half-life. The compound is being studied successfully since the 2000s due to visceral fat degrading properties. The relative half-life of the compound is 5.8-8.1 days. However, addition of IGF-1 may increase the half-life up to 30 days. Further studies are being conducted to explore the benefits of CJC 1295 (DAC) on deep sleep or slow wave of the brain.
Growth hormone and somatostatin are released in pulses in the anterior lobe of the pituitary gland, to counter the effects of somatostatin the level of CJC-1295 DAC should be kept at a high level throughout. Studies conducted in the past two decades led to the introduction of different growth hormone secretagogues. However, more research is being conducted to ascertain the effectiveness and efficacy of the hormone. Moreover, an enhanced level of growth hormone in the system has a positive effect in fat metabolism. CJC-1295 DAC has a positive feedback mechanism on the production of Ghrelin a hormone known to induce feelings of hunger, gastric emptying, and motility. Further studies reveal that a combined blend of the polypeptide with growth hormone hexapapeptide increases the rate of release of IGF-1 without any considerable effect on prolactin. The main feature of the polypeptide is the existence of the DAC or drug affinity complex, which is formed from lysine binding to maleimidoproprionic acid.